This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on X or LinkedIn  

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeti

02 Jun 2023

Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting Scancell Holdings plc ("Scancell" or the "Company") Scancell to present ModiFY Phase 1/2 cancer vaccine clinical trial protocol and early efficacy data at the American Society of Clinical Oncology Meeting ModiFY trial progressing through monotherapy expansion cohorts and combination... Read more

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

17 May 2023

OXFORD, England--(BUSINESS WIRE)--Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, Ph.D. as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics... Read more

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage

15 May 2023

Third clinical molecule from collaboration with Sumitomo Pharma to enter Phase 1 trials DSP-2342, a dual 5-HT2A/5-HT7 antagonist to be assessed in psychiatric disease OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that Sumitomo Pharma Co., Ltd. (‘Sumitomo Pharma’) plans to initiate a Phase 1 clinical study of DSP-2342 in the United States. DSP-2342 is a highly-selective bispecific small molecule with... Read more

OrganOx Chief Medical Officer, Professor Peter Friend, Elected as Vice President of Royal College of Surgeons of England

OrganOx Chief Medical Officer, Professor Peter Friend, Elected as Vice President of Royal College of Surgeons of England

12 May 2023

Oxford, United Kingdom, 12 May 2023: OrganOx Ltd (“OrganOx” or the “Company”), a world-leading medical technology company committed to making every donated organ count with metra®, a fully automated normothermic machine perfusion (NMP) device for liver transplantation, today announces that Chief Medical Officer, Professor Peter Friend, has been elected as Vice President of the Royal College of Surgeons of England. Professor Friend, a... Read more

Professor Andrew L. Hopkins elected Fellow of the Royal Society

Professor Andrew L. Hopkins elected Fellow of the Royal Society

10 May 2023

Professor Andrew L. Hopkins elected Fellow of the Royal Society May 10, 2023 Changing the world through exceptional science and technology OXFORD, England--(BUSINESS WIRE)-- Professor Andrew Hopkins DPhil LLD FRSE, founder and Chief Executive of Exscientia plc (Nasdaq: EXAI), has been elected a Fellow of the Royal Society, the world’s oldest and most influential scientific society. Andrew is one of the UK’s most eminent science and... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More